Indications and uses
Norepinephrine Bitartrate in 5% Dextrose Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension.
Norepinephrine Bitartrate in 5% Dextrose Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension.
Correct Hypovolemia Address hypovolemia before initiation of norepinephrine bitartrate in 5% dextrose injection therapy. If the patient does not respond to therapy, suspect occult hypovolemia [see Warnings and Precautions ( 5.1 )]. Administration Norepinephrine bitartrate in 5% dextrose injection is a ready to administer product that requires no further dilution prior to infusion. Parenteral drug products should b...
Norepinephrine Bitartrate in 5% Dextrose Injection intravenous infusion is available in single-dose, ready-to-use containers in an amber/foil overwrap. Each 250 mL of Norepinephrine Bitartrate in 5% Dextrose Injection, 4 mg per 250 mL and 8 mg per 250 mL contains the equivalent of 4 mg and 8 mg of norepinephrine, respectively (provided as norepinephrine bitartrate monohydrate). Norepinephrine Bitartrate in 5% Dext...
Norepinephrine Bitartrate in 5% Dextrose Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension.
Correct Hypovolemia
Address hypovolemia before initiation of norepinephrine bitartrate in 5% dextrose injection therapy. If the patient does not respond to therapy, suspect occult hypovolemia [see Warnings and Precautions (5.1)].
Administration
Norepinephrine bitartrate in 5% dextrose injection is a ready to administer product that requires no further dilution prior to infusion. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate.
Infuse norepinephrine bitartrate in 5% dextrose injection into a large vein. Avoid infusions into the veins of the leg in the elderly or in patients with occlusive vascular disease of the legs [see Warnings and Precautions (5.1)]. Avoid using a catheter-tie-in technique.
The choice of appropriate concentration of norepinephrine bitartrate in 5% dextrose injection depends on clinical fluid volume requirements. Use higher concentration solutions in patients requiring fluid restriction.
Discontinuation
When discontinuing the infusion, reduce the flow rate gradually. Avoid abrupt withdrawal.
After an initial dosage of 8 to 12 mcg per minute via intravenous infusion, assess patient response and adjust dosage to maintain desired hemodynamic effect. Monitor blood pressure every two minutes until the desired hemodynamic effect is achieved, and then monitor blood pressure every five minutes for the duration of the infusion.
Typical maintenance intravenous dosage is 2 to 4 mcg per minute.
Avoid contact with iron salts, alkalis, or oxidizing agents.
Whole blood or plasma, if indicated to increase blood volume, should be administered separately.
Injection: Norepinephrine bitartrate in 5% dextrose is a colorless to slightly yellow solution for intravenous infusion, supplied in 250 mL single dose containers as:
None.
Administration of norepinephrine bitartrate to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite “normal” blood pressure. Address hypovolemia prior to initiating norepinephrine bitartrate [see Dosage and Administration (2.1)]. Avoid norepinephrine bitartrate in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction.
Gangrene of the extremities has occurred in patients with occlusive or thrombotic vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients.
Extravasation of norepinephrine bitartrate may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein, check the infusion site frequently for free flow, and monitor for signs of extravasation [see Dosage and Administration (2.1)].
Emergency Treatment of Extravasation
To prevent sloughing and necrosis in areas in which extravasation has occurred, infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults.
Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.
Sudden cessation of the infusion rate may result in marked hypotension. When discontinuing the infusion, gradually reduce the norepinephrine bitartrate infusion rate while expanding blood volume with intravenous fluids.
Norepinephrine bitartrate elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias.
The following serious adverse reactions are described in greater detail in other sections:
The most common adverse reactions are hypertension and bradycardia. The following adverse reactions can occur:
Nervous system disorders: Anxiety, headache
Respiratory disorders: Respiratory difficulty, pulmonary edema
General disorders and administration site conditions: Extravasation, injection site necrosis [see Warnings and Precautions (5.1)].
Co-administration of norepinephrine bitartrate with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension.
If administration of norepinephrine bitartrate cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.
Co-administration of norepinephrine bitartrate with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If administration of norepinephrine bitartrate cannot be avoided in these patients, monitor for hypertension.
Norepinephrine bitartrate can decrease insulin sensitivity and raise blood glucose. Monitor glucose and consider dosage adjustment of antidiabetic drugs.
Concomitant use of norepinephrine bitartrate with halogenated anesthetics (e.g., cyclopropane, desflurane, enflurane, isoflurane, and sevoflurane) may lead to ventricular tachycardia or ventricular fibrillation. Monitor cardiac rhythm in patients receiving concomitant halogenated anesthetics.
Risk Summary
Limited published data consisting of a small number of case reports and multiple small trials involving the use of norepinephrine in pregnant women at the time of delivery have not identified an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus from hypotension associated with septic shock, myocardial infarction and stroke which are medical emergencies in pregnancy and can be fatal if left untreated. (see Clinical Considerations). In animal reproduction studies, using high doses of intravenous norepinephrine resulted in lowered maternal placental blood flow. Clinical relevance to changes in the human fetus is unknown since the average maintenance dose is ten times lower (see Data). Increased fetal reabsorptions were observed in pregnant hamsters after receiving daily injections at approximately 2 times the maximum recommended dose on a mg/m3 basis for four days during organogenesis (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Hypotension associated with septic shock, myocardial infarction, and stroke are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic shock, myocardial infarction and stroke may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of norepinephrine on the fetus.
Data
Animal Data
A study in pregnant sheep receiving high doses of intravenous norepinephrine (40 mcg/min, at approximately 10 times the average maintenance dose of 2 to 4 mcg/min in human, on a mg/kg basis) exhibited a significant decrease in maternal placental blood flow. Decreases in fetal oxygenation, urine and lung liquid flow were also observed.
Norepinephrine administration to pregnant rats on Gestation Day 16 or 17 resulted in cataract production in rat fetuses.
In hamsters, an increased number of resorptions (29.1% in study group vs. 3.4% in control group), fetal microscopic liver abnormalities and delayed skeletal ossification were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day from Gestation Day 7 to 10).
Risk Summary
There are no data on the presence of norepinephrine in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. Clinically relevant exposure to the infant is not expected based on the short half-life and poor oral bioavailability of norepinephrine.
Safety and effectiveness in pediatric patients have not been established.
Clinical studies of norepinephrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Avoid administration of norepinephrine bitartrate into the veins in the leg in elderly patients [see Warnings and Precautions (5.1)].
Overdosage with norepinephrine bitartrate may result in headache, severe hypertension, reflex bradycardia, marked increase in peripheral resistance, and decreased cardiac output.
In case of overdosage, discontinue norepinephrine bitartrate until the condition of the patient stabilizes.
Norepinephrine Bitartrate in 5% Dextrose Injection contains norepinephrine, a sympathomimetic amine. Norepinephrine is sometimes referred to as l-arterenol/Levarterenol or l-norepinephrine which differs from epinephrine by the absence of a methyl group on the nitrogen atom.
Chemically, norepinephrine bitartrate monohydrate is (-)-α-(aminomethyl) -3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt) monohydrate and has the following structural formula:

Norepinephrine is sparingly soluble in water, very slightly soluble in alcohol and ether, and readily soluble in acids.
Norepinephrine Bitartrate in 5% Dextrose Injection is supplied as a sterile aqueous solution administered by intravenous infusion. Each mL contains the equivalent of 16 or 32 micrograms of norepinephrine base supplied as 31.90 and 63.80 micrograms per mL of norepinephrine bitartrate monohydrate. It contains dextrose monohydrate (50 mg per mL) and may contain hydrochloric acid and/or sodium hydroxide for pH adjustment. It has a pH of 3.5 to 3.9. The air in the containers has been displaced by nitrogen gas.
Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
The primary pharmacodynamic effects of norepinephrine are cardiac stimulation and vasoconstriction. Cardiac output is generally unaffected, although it can be decreased, and total peripheral resistance is also elevated. The elevation in resistance and pressure result in reflex vagal activity, which slows the heart rate and increases stroke volume. The elevation in vascular tone or resistance reduces blood flow to the major abdominal organs as well as to skeletal muscle. Coronary blood flow is substantially increased secondary to the indirect effects of alpha stimulation. After intravenous administration, a pressor response occurs rapidly and reaches steady state within 5 minutes. The pharmacologic actions of norepinephrine are terminated primarily by uptake and metabolism in sympathetic nerve endings. The pressor action stops within 1 to 2 minutes after the infusion is discontinued.
Absorption
Following initiation of intravenous infusion, the steady state plasma concentration is achieved in 5 min.
Distribution
Plasma protein binding of norepinephrine is approximately 25%. It is mainly bound to plasma albumin and to a smaller extent to prealbumin and alpha 1-acid glycoprotein. The volume of distribution is 8.8 L. Norepinephrine localizes mainly in sympathetic nervous tissue. It crosses the placenta but not the blood-brain barrier.
Elimination
The mean half-life of norepinephrine is approximately 2.4 min. The average metabolic clearance is 3.1 L/min.
Metabolism
Norepinephrine is metabolized in the liver and other tissues by a combination of reactions involving the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The major metabolites are normetanephrine and 3-methoxy-4-hydroxy mandelic acid (vanillylmandelic acid, VMA), both of which are inactive. Other inactive metabolites include 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol.
Excretion
Norepinephrine metabolites are excreted in urine primarily as the sulfate conjugates and, to a lesser extent, as the glucuronide conjugates. Only small quantities of norepinephrine are excreted unchanged.
Carcinogenesis, mutagenesis, and fertility studies have not been performed.
Norepinephrine Bitartrate in 5% Dextrose Injection intravenous infusion is available in single-dose, ready-to-use containers in an amber/foil overwrap. Each 250 mL of Norepinephrine Bitartrate in 5% Dextrose Injection, 4 mg per 250 mL and 8 mg per 250 mL contains the equivalent of 4 mg and 8 mg of norepinephrine, respectively (provided as norepinephrine bitartrate monohydrate). Norepinephrine Bitartrate in 5% Dextrose Injection is available in the following:
| NDC | Norepinephrine Bitartrate in 5% Dextrose Injection | Package Factor |
| (16 mcg per mL) | ||
| 25021-325-84 | 4 mg per 250 mL Single-Dose Bag | 10 bags per carton |
| NDC | Norepinephrine Bitartrate in 5% Dextrose Injection | Package Factor |
| (32 mcg per mL) | ||
| 25021-326-84 | 8 mg per 250 mL Single-Dose Bag | 10 bags per carton |
Storage Conditions
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Once the overwrap is removed, the bag can be stored at room temperature for up to 30 days.
Protect from light. Keep in overwrap until ready to use.
Discard unused portion.
Sterile, Nonpyrogenic, Preservative-free, PVC-free, DEHP-free.
The container closure is not made with natural rubber latex.
Risk of Tissue Damage
Advise the patient, family, or caregiver to report signs of extravasation urgently [see Warnings and Precautions (5.1)].
sagent®
Mfd. for SAGENT Pharmaceuticals
Schaumburg, IL 60173 (USA)
Made in India
©2025 Sagent Pharmaceuticals
August 2025
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 25021-325 | 25021-325-84 |
| 25021-326 | 25021-326-84 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NOREPINEPHRINE BITARTRATE | IFY5PE3ZRW | ACTIM |
| Dextrose Monohydrate | LX22YL083G | IACT |
| Hydrochloric Acid | QTT17582CB | IACT |
| Sodium Hydroxide | 55X04QC32I | IACT |
| NOREPINEPHRINE BITARTRATE | IFY5PE3ZRW | ACTIM |
| Dextrose Monohydrate | LX22YL083G | IACT |
| Hydrochloric Acid | QTT17582CB | IACT |
| Sodium Hydroxide | 55X04QC32I | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | NOREPINEPHRINE BITARTRATE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | |
| A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | NOREPINEPHRINE BITARTRATE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 |
| Application-product | TE code |
|---|---|
| A219692-001 | AP |
| A219692-002 | AP |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | 31067a03dcf5… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219692-001 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219692-002 | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2025-08-11 | a50c72e98297… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A219692-001 | AP | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A219692-002 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A219692-001 | AP | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A219692-002 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A219692-001 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A219692-002 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A219692-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A219692-002 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A219692-001 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A219692-002 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219692-001 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219692-002 | AP | 1 | 31067a03dcf5… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219692-001 | AP | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219692-002 | AP | 1 | a50c72e98297… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Norepinephrine Bitartrate | NOREPINEPHRINE BITARTRATE | Northstar Rx LLC | 5fbd0e3b-703b-412e-8b71-bd0a0dbf4500 | 2026-10-16 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine Bitartrate | NOREPINEPHRINE BITARTRATE | Breckenridge Pharmaceutical, Inc. | 109aa5e6-4e42-4131-97b0-f24d3a4cb4e8 | 2026-08-27 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| NOREPINEPHRINE BITARTRATE | NOREPINEPHRINE BITARTRATE | HF Acquisition Co LLC, DBA HealthFirst | c90d875c-8e6e-284e-e053-2a95a90a334f | 2026-06-19 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine | NOREPINEPHRINE BITARTRATE | Long Grove Pharmaceuticals, LLC | 759807dd-61a8-4f6f-8bf5-f6ee773c81bc | 2026-04-30 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE | NOREPINEPHRINE BITARTRATE | WG Critical Care, LLC | ddbef60d-c20a-4ada-928f-e87074c08a54 | 2026-04-01 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| NOREPINEPHRINE BITARTRATE | NOREPINEPHRINE BITARTRATE | Baxter Healthcare Corporation | 6363e9b4-29df-4553-904d-a563e5adda6e | 2026-02-06 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| norepinephrine bitartrate | NOREPINEPHRINE BITARTRATE | Avenacy, LLC | dd4b7827-2fe9-4427-a40a-60f275611bf4 | 2026-02-01 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| norepinephrine bitartrate | NOREPINEPHRINE BITARTRATE | Novadoz Pharmaceuticals LLC | 4b054c27-ed64-40e2-8eba-b7f2ec780a82 | 2025-12-16 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| NOREPINEPHRINE BITARTRATE | NOREPINEPHRINE BITARTRATE | Anthea Pharma Private Limited | 52e22892-4fc3-4f53-9f39-0b5c66da3040 | 2025-11-25 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| NOREPINEPHRINE BITARTRATE | NOREPINEPHRINE BITARTRATE | BIOCON PHARMA INC. | 0ea48ab6-e166-df31-b132-70ef982a2d02 | 2025-06-17 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| LEVOPHED | NOREPINEPHRINE BITARTRATE | Hospira, Inc. | 2c7dd2b0-cc10-4db6-bf56-6eb154ebeb10 | 2025-06-12 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine bitartrate | NOREPINEPHRINE BITARTRATE | Camber Pharmaceuticals, Inc. | baba1002-8b62-4a24-a4e1-53e7a59c785a | 2025-06-12 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| LEVOPHED | NOREPINEPHRINE BITARTRATE | Hospira, Inc. | c4de72a8-2a75-4984-ce90-e4870226dc12 | 2025-06-12 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine Bitartrate | NOREPINEPHRINE BITARTRATE | Rising Pharma Holdings, Inc. | e6669ed6-9ebc-4b2d-9a8c-5e318fbd18b4 | 2024-11-01 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| NOREPINEPHRINE BITARTRATE | NOREPINEPHRINE BITARTRATE | Caplin Steriles Limited | 2ffda6e7-d45d-4af3-a3b1-250a4c95e736 | 2024-09-28 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine Bitartrate | NOREPINEPHRINE BITARTRATE | Meitheal Pharmaceuticals Inc. | 53578ac5-b510-4698-a097-f785bfea9fc0 | 2024-06-24 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine bitartrate | NOREPINEPHRINE BITARTRATE | Gland Pharma Limited | dec04acd-8e66-43c7-80b0-468802eba093 | 2024-05-24 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine Bitartrate | NOREPINEPHRINE BITARTRATE | Hikma Pharmaceuticals USA Inc. | 39cda6c6-3857-4028-80cf-aef135f8c7e6 | 2024-01-10 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine Bitartrate | NOREPINEPHRINE BITARTRATE | Sagent Pharmaceuticals | cc9ecec5-3bd7-4132-9745-7666bac8ceac | 2023-12-31 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
| Norepinephrine Bitartrate | NOREPINEPHRINE BITARTRATE | BE Pharmaceuticals Inc. | c42d425a-094e-4390-b4f9-4bb4b0fbc7d0 | 2023-12-30 | Warnings, Adverse reactions | NOREPINEPHRINE BITARTRATE |
Adverse event summaries are temporarily unavailable. Other product information remains available.